lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed and are posted here as part of a 12-month trial. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

VEGF Receptors Peptide Vaccine in Neurofibromatosis Type 2: A Single-Arm, Open-Label, Phase 1/2 Trial

72 Pages Posted: 2 Mar 2019

See all articles by Ryota Tamura

Ryota Tamura

Keio University - Department of Neurosurgery

Masato Fujioka

Keio University - Department of Otorhinolaryngology, Head and Neck Surgery

Yukina Morimoto

Keio University - Department of Neurosurgery

Kentaro Ohara

Keio University - Department of Pathology

Kenzo Kosugi

Keio University - Department of Neurosurgery

Yumiko Oishi

Keio University - Department of Neurosurgery

Mizuto Sato

Keio University - Department of Neurosurgery

Ryo Ueda

Keio University - Department of Neurosurgery

Hirokazu Fujiwara

Keio University - Department of Radiology

Shinobu Noji

Keio University - Division of Cellular Signaling Institute for Advanced Medical Research

Naoki Oishi

Keio University - Department of Otorhinolaryngology, Head and Neck Surgery

Kaoru Ogawa

Keio University - Department of Otorhinolaryngology, Head and Neck Surgery

Yutaka Kawakami

Keio University - Division of Cellular Signaling Institute for Advanced Medical Research

Takayuki Ohira

Keio University - Department of Neurosurgery

Kazunari Yoshida

Keio University - Department of Neurosurgery

Masahiro Toda

Keio University - Department of Neurosurgery

More...

Abstract

Background: There is no established therapy for neurofibromatosis type 2 (NF2). Bevacizumab has recently proved efficacious for the treatment of NF2, presumably because vascular endothelial growth factor (VEGF) is essential for NF2 tumor growth. Theoretically, VEGF receptors (VEGFRs)-specific cytotoxic T lymphocytes (CTLs) can kill both tumor vessel cells and tumor cells expressing VEGFRs. The aim of the current study was to evaluate the safety and efficacy of a VEGFRs peptide vaccine in NF2 patients.

Methods: An exploratory clinical study of VEGFRs peptide vaccine was conducted in 7 patients with progressive NF2-derived schwannomas. Tumor volume and blood flow were analyzed via magnetic resonance imaging and computed tomography perfusion, and hearing was evaluated via word recognition scores (WRSs) and pure-tone audiograms. To investigate the therapeutic mechanisms involved in this novel therapy, CTL responses and VEGFRs expression in schwannomas were analyzed.

Findings: Hearing improved in 3 of the 6 assessable patients (50%), with WRS increases of more than 10%. Reductions of > 20% in more than one tumor were observed in 2 patients, including a case in which bevacizumab had not been effective (case 6). There were no severe adverse events related to the vaccine. Both VEGFR1 specific and VEGFR2-specific CTLs were induced in 6 patients, and in the remaining patient VEGFR1-specific CTLs were induced. Histological analysis of schwannomas revealed high VEGFRs expression both in tumor vessels and in tumor cells. Surgery was performed after vaccination in two patients, and significant reductions in VEGFRs expression in schwannomas were observed.

Interpretation: This is the first clinical immunotherapy study demonstrating the safety and efficacy of VEGFRs peptide vaccination in patients with NF2.

Trial Registration Number: The trial was registered at UMIN (UMIN000023565).

Funding Statement: The authors state: "None."

Declaration of Interests: The authors have no personal financial or institutional interests in any of the drugs, materials, or devices mentioned in this article.

Ethics Approval Statement: All protocols were approved by the Keio University Ethics Committee, and conducted in accordance with the Helsinki declaration on experimentation on human subjects.

Keywords: VEGF receptor; peptide vaccine; NF2; schwannoma: meningioma

Suggested Citation

Tamura, Ryota and Fujioka, Masato and Morimoto, Yukina and Ohara, Kentaro and Kosugi, Kenzo and Oishi, Yumiko and Sato, Mizuto and Ueda, Ryo and Fujiwara, Hirokazu and Noji, Shinobu and Oishi, Naoki and Ogawa, Kaoru and Kawakami, Yutaka and Ohira, Takayuki and Yoshida, Kazunari and Toda, Masahiro, VEGF Receptors Peptide Vaccine in Neurofibromatosis Type 2: A Single-Arm, Open-Label, Phase 1/2 Trial (February 27, 2019). Available at SSRN: https://ssrn.com/abstract=3343652

Ryota Tamura

Keio University - Department of Neurosurgery

Tokyo
Japan

Masato Fujioka

Keio University - Department of Otorhinolaryngology, Head and Neck Surgery

Tokyo
Japan

Yukina Morimoto

Keio University - Department of Neurosurgery

Tokyo
Japan

Kentaro Ohara

Keio University - Department of Pathology

Tokyo
Japan

Kenzo Kosugi

Keio University - Department of Neurosurgery

Tokyo
Japan

Yumiko Oishi

Keio University - Department of Neurosurgery

Tokyo
Japan

Mizuto Sato

Keio University - Department of Neurosurgery

Tokyo
Japan

Ryo Ueda

Keio University - Department of Neurosurgery

Tokyo
Japan

Hirokazu Fujiwara

Keio University - Department of Radiology

Tokyo
Japan

Shinobu Noji

Keio University - Division of Cellular Signaling Institute for Advanced Medical Research

Tokyo
Japan

Naoki Oishi

Keio University - Department of Otorhinolaryngology, Head and Neck Surgery

Tokyo
Japan

Kaoru Ogawa

Keio University - Department of Otorhinolaryngology, Head and Neck Surgery

Tokyo
Japan

Yutaka Kawakami

Keio University - Division of Cellular Signaling Institute for Advanced Medical Research

Tokyo
Japan

Takayuki Ohira

Keio University - Department of Neurosurgery

Tokyo
Japan

Kazunari Yoshida

Keio University - Department of Neurosurgery

Tokyo
Japan

Masahiro Toda (Contact Author)

Keio University - Department of Neurosurgery ( email )

Tokyo
Japan

Click here to go to TheLancet.com

Go to TheLancet.com

Paper statistics

Abstract Views
120
Downloads
14